10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Pleural mesothelioma grows in the lining of the lung after asbestos exposure and causes breathlessness and chest pain from fluid and thickening. It is rarely curable; the first-line choice is nivolumab with ipilimumab or pembrolizumab with chemotherapy, and in the MARS 2 trial surgery to remove the lining gave worse survival to two years than chemotherapy alone.
Pleural mesothelioma is the commonest form of mesothelioma. It presents with pleural effusion, breathlessness and chest wall pain 20 to 50 years after asbestos exposure, and is diagnosed by thoracoscopic biopsy with immunohistochemistry (calretinin, WT1, D2-40) and loss of BAP1 or MTAP. Epithelioid histology, about two thirds of cases, carries a better outlook than biphasic or sarcomatoid disease. CheckMate 743 made nivolumab plus ipilimumab the first new first-line treatment in 16 years, and KEYNOTE-483 added pembrolizumab with platinum-pemetrexed; both are now standard, with histology guiding the choice. MARS 2 found worse survival to two years (median 19.3 against 24.8 months) and more serious adverse events with extended pleurectomy decortication plus chemotherapy than with chemotherapy alone, which has moved practice away from radical surgery; the ASCO 2025 guideline update on surgery could not be re-read on 18 November 2026 because the publisher refused a script. Hemithoracic radiotherapy, tumour treating fields and mesothelin-directed therapies are the main lines of research.
| Setting | Approach | Guideline |
|---|---|---|
| Diagnosis and staging | CT and PET-CT; thoracoscopic biopsy with an immunohistochemistry panel; histology and BAP1/MTAP status recorded because they drive treatment. | not mapped |
| First line, non-epithelioid | Nivolumab plus ipilimumab (CheckMate 743). | not mapped |
| First line, epithelioid | Pembrolizumab with platinum-pemetrexed (KEYNOTE-483), nivolumab plus ipilimumab, or platinum-pemetrexed with or without bevacizumab, by fitness and preference. | not mapped |
| Surgery | Extended pleurectomy decortication gave worse two-year survival than chemotherapy alone in MARS 2, so radical surgery is a matter for specialist discussion and trials; talc pleurodesis or an indwelling pleural catheter controls effusion. | not mapped |
| Second line | Nivolumab (CONFIRM) if not given first line; chemotherapy rechallenge or gemcitabine or vinorelbine after immunotherapy. | not mapped |